Diabetes Mellitus Secondary to Cushing’s Disease
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Associated with important comorbidities that significantly reduce patients' overall wellbeing and life expectancy, Cushing's disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortisol excess, treating CD also serves to alleviate impaired glucose metabolism. Although transsphenoidal pituitary surgery remains the first-line treatment for CD, it is not always effective and other treatment strategies may be necessary. This work examines the main features of DM secondary to CD and focuses on antidiabetic drugs and how cortisol-lowering medication affects glucose metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 1×
“Metformin remains the first-line therapy of hyperglycemia in CD (31).”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 receptor agonists act by enhancing glucose-induced biosynthesis and insulin secretion, inhibiting glucagon secretion, delaying gastric emptying, and reducing appetite (48, 49).”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“The overexpression of 11 β HSD1 in adipose tissue is correlated with the development of insulin resistance and obesity (22).”
BackgroundTreatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853 · cited 1×
“Despite increasing interest in medical therapy, the first-line approach still remains transsphenoidal surgery (26) which provides, when it is performed by an experienced neurosurgeon, a mean remission rate of 77.8% (3, 27).”
BackgroundInfluentialBruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692 · cited 1×
“Pasireotide, a multi-somatostatin receptor ligand that is able to bind four of the five known SSTR subtypes (SSTRs1–3 and SSTR5) with a 40-fold greater binding affinity for SSTR5 with respect to octreotide (59, 60), was the first agent to be approved for the treatment of adult CD patients.”
BackgroundGlucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans
Bamberger, C. M., Bamberger, A. M., de Castro, M., & Chrousos, G. P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117943 · Cited by 642 · cited 1×
“The A3669G polymorphism has been found to play a protective role in CD (24) by producing glucocorticoid resistance that increases the expression and stabilization of the dominant-negative GR-β splice variant (24, 25).”
BackgroundA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Glucocorticoids, metabolism and metabolic diseases
Vegiopoulos, A., & Herzig, S. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.015 · Cited by 535 · cited 1×
“Finally, glucocorticoid receptor polymorphisms may also play a role in the development of metabolic complications (23).”
BackgroundFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479 · cited 1×
“After 24 weeks of mifepristone treatment, fasting plasma glucose and HbA1c decreased, respectively, from 8.3 ± 4.1 to 5.8 ± 2.1 mmol/L and from 7.43 ± 1.52 to 6.29 ± 0.99%, leading to a reduction in the number of antidiabetic medications the patients were taking (99).”
BackgroundInfluentialMechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
DEFRONZO, R. A., BARZILAI, N., & SIMONSON, D. C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1294 · Cited by 408
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Berry, D. C., & Noy, N. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01742-08 · Cited by 345
Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Van de Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E., & Van Weel, C. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003639.pub2 · Cited by 335 · cited 1×
“Acarbose inhibits the enzymatic cleavage of complex carbohydrates, delaying their absorption and thereby reducing postprandial glycemic excursions (36).”
BackgroundVerhelst, J. A., Trainer, P. J., Howlett, T. A., Perry, L., Rees, L. H., Grossman, A. B., Wass, J. A. H., & Sesser, G. M. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03517.x · Cited by 308 · cited 1×
“Another study reported a significant improvement in glucose metabolism in more than 80% of CD patients (94).”
BackgroundThe Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296 · cited 1×
“Other positive effects such as weight loss and blood pressure reduction have also been noted (50).”
BackgroundKetoconazole in Cushing's disease: is it worth a try?
Castinetti, F., Guignat, L., Giraud, P., Muller, M., Kamenicky, P., Drui, D., Caron, P., Luca, F., Donadille, B., Vantyghem, M. C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3628 · Cited by 285 · cited 2×
“At doses of 200–1,200 mg/day, it is able to improve glucose metabolism in CD patients (87–90).”
BackgroundInfluentialHigh cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278 · cited 5×
“Clin Endocrinol (Oxf) (2004) 61(6):768–77.”
BackgroundInfluentialGender-Related Differences in the Presentation and Course of Cushing’s Disease
Giraldi, F. P., Moro, M., & Cavagnini, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021518 · Cited by 260
Daniel, E., Aylwin, S., Mustafa, O., Ball, S., Munir, A., Boelaert, K., Chortis, V., Cuthbertson, D. J., Daousi, C., Rajeev, S. P., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2616 · Cited by 231 · cited 1×
“The agent’s effects on glucose metabolism were not analyzed by the study, but hypoglycemia was reported in three patients taking antidiabetic drugs following an improvement in hypercortisolism (95).”
BackgroundGlucocorticoids and the regulation of growth hormone secretion
Mazziotti, G., & Giustina, A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.5 · Cited by 206
Cabergoline monotherapy in the long-term treatment of Cushing's disease
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0382 · Cited by 202
Ketoconazole treatment in Cushing’s syndrome: experience in 34 patients
Sonino, N., Boscaro, M., Paoletta, A., Mantero, F., & Zillotto, D. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb03547.x · Cited by 201 · cited 1×
“At doses of 200–1,200 mg/day, it is able to improve glucose metabolism in CD patients (87–90).”
BackgroundDiabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193 · cited 1×
“Pioglitazone treatment has not, however, been found to reduce ACTH or cortisol levels in CD (40, 41) and may cause weight gain and/or edema which may worsen the CD patient’s clinical condition (4, 42, 43).”
BackgroundPathophysiology of Diabetes Mellitus in Cushing’s Syndrome
Pivonello, R., De Leo, M., Vitale, P., Cozzolino, A., Simeoli, C., De Martino, M. C., Lombardi, G., & Colao, A. (2010) · Neuroendocrinology · doi:10.1159/000314319 · Cited by 190
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center
Baudry, C., Coste, J., Bou Khalil, R., Silvera, S., Guignat, L., Guibourdenche, J., Abbas, H., Legmann, P., Bertagna, X., & Bertherat, J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0358 · Cited by 187 · cited 1×
“%) of those receiving the drug for at least 6 months (98).”
Background11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease
Castinetti, F., Morange, I., Jaquet, P., Conte-Devolx, B., & Brue, T. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0514 · Cited by 175
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140 · cited 10×
“Approximately 10–30% of patients have impaired glucose tolerance, and the overall prevalence of glucose metabolism impairments reaches nearly 70% of cases (4).”
BackgroundInfluentialSelf-citationDiabetes-Haufigkeit bei Akromegalie und Cushing-Syndrom
Biering, H., Knappe, G., Gerl, H., & Lochs, H. (2000) · Acta Medica Austriaca · doi:10.1046/j.1563-2571.2000.00106.x · Cited by 113
Diagnosis and complications of Cushing’s disease: gender-related differences
Zilio, M., Barbot, M., Ceccato, F., Camozzi, V., Bilora, F., Casonato, A., Frigo, A. C., Albiger, N., Daidone, V., Mazzai, L., et al. (2014) · Clinical Endocrinology · doi:10.1111/cen.12299 · Cited by 93 · cited 1×
“No gender-related differences in prevalence have been noted (5).”
BackgroundA reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome
Valassi, E., Crespo, I., Gich, I., Rodríguez, J., & Webb, S. M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04424.x · Cited by 91
Is diabetes in Cushing’s syndrome only a consequence of hypercortisolism?
Giordano, C., Guarnotta, V., Pivonello, R., Amato, M. C., Simeoli, C., Ciresi, A., Cozzolino, A., & Colao, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0754 · Cited by 79
Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?
On behalf of ABC Group, Scillitani, A., Mazziotti, G., Di Somma, C., Moretti, S., Stigliano, A., Pivonello, R., Giustina, A., & Colao, A. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2588-y · Cited by 62
Epinephrine and the regulation of glucose metabolism: effect of diabetes and hormonal interactions
Sherwin, R. S., Shamoon, H., Hendler, R., Saccà, L., Eigler, N., & Walesky, M. (1980) · Metabolism · doi:10.1016/0026-0495(80)90024-4 · Cited by 61 · cited 1×
“Cortisol is necessary for the normal development of the adrenal medulla that is specialized in the synthesis, storage, and secretion of catecholamines from chromaffin cells; its excess enhances the adrenergic-mediated increase in gluconeogenesis (16).”
BackgroundTrementino, L., Appolloni, G., Concettoni, C., Cardinaletti, M., Boscaro, M., & Arnaldi, G. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0722 · Cited by 53 · cited 1×
“The A3669G polymorphism has been found to play a protective role in CD (24) by producing glucocorticoid resistance that increases the expression and stabilization of the dominant-negative GR-β splice variant (24, 25).”
BackgroundBaroni, M. G., Giorgino, F., Pezzino, V., Scaroni, C., & Avogaro, A. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0404-6 · Cited by 41
Self-citationBurt, M. G., Drake, S. M., Aguilar‐Loza, N. R., Esterman, A., Stranks, S. N., & Roberts, G. W. (2015) · Internal Medicine Journal · doi:10.1111/imj.12680 · Cited by 38 · cited 1×
“Basal-bolus insulin therapy including basal, prandial, and a supplemental correction-factor insulin is considered the most flexible option for patients with hypercortisolism (58).”
BackgroundKetoconazole enantiomer for the treatment of diabetes mellitus
Arakaki, R., & Welles, B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903381411 · Cited by 21
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
A practical guide for the management of steroid induced hyperglycaemia in the hospital
Aberer, F., Hochfellner, D. A., Sourij, H., & Mader, J. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102154 · Cited by 110
Sleep, circadian rhythms, and type 2 diabetes mellitus
Parameswaran, G., & Ray, D. W. (2022) · Clinical Endocrinology · doi:10.1111/cen.14607 · Cited by 85
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Self-citationDynamic modulation of glucose utilisation by glucocorticoid rhythms in health and disease
Zavala, E., Gil-Gómez, C. A., Wedgwood, K. C. A., Burgess, R., Tsaneva-Atanasova, K., & Herrera-Valdez, M. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.27.968354 · Cited by 8
Metadata
- Authors
- Barbot, M., Ceccato, F., & Scaroni, C.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-05
- Volume
- 9
- Pages
- 284-284
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2803299845
- Cited by
- 75
- References
- 43
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.